Brexit: What next for the pharmaceutical and life sciences sector?

Brexit is the most significant upset to the European order since the European Economic Community was founded in 1957, casting waves of of constitutional, political and economic impacts that will be seen for years to come. 

Businesses can expect a variety of changes which need to be anticipated and mitigated. This is especially true for highly regulated industries such as the Pharmaceutical and Life Sciences industry.

In this series of articles we will explore some of the potential changes that can be expected across different functional areas.



{{contentList.dataService.numberHits}} {{contentList.dataService.numberHits == 1 ? 'result' : 'results'}}

Contact us

Johnathon Marshall

Johnathon Marshall

Partner, Health Industries, Procurement and Supply Chain Management, PwC United Kingdom

Tel: +44 (0)7736 350447

Follow us